{"type":"trials","record":{"id":41887,"source_id":"clinicaltrials-gov","external_id":"NCT06718816","title":"Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD","brief_summary":"This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","enrollment":21,"countries":["China"],"start_date":"2024-12-09","completion_date":"2029-06-30","last_update_date":"2024-12-05","source_url":"https://clinicaltrials.gov/study/NCT06718816","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Beijing Anlong Biopharmaceutical Co., Ltd.","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["AE/SAE — month 48","Best Corrected Visual Acuity(BCVA) — month 48","The mean and frequency of anti-VEGF injections — month 48"],"design_description":null,"source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration (wAMD)"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06718816","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-12-09 to 2029-06-30","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.887Z","intervention":[],"participants":21,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["AE/SAE — month 48","Best Corrected Visual Acuity(BCVA) — month 48","The mean and frequency of anti-VEGF injections — month 48"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41887","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}